Alpha Cognition Enrolls First Patient in BEACON Phase 4 Study Evaluating ZUNVEYL® in Long-Term Care Patients with Alzheimer’s Disease
Alpha Cognition Inc. a clinical-stage biopharmaceutical company focused on advancing innovative therapies for neurodegenerative diseases, today announced a significant milestone in its clinical development program: the enrollment of the first patient in the BEACON study. BEACON is a Phase 4, real-world effectiveness study designed to evaluate the impact of Alpha Cognition’s novel therapy, ZUNVEYL®, in patients with Alzheimer’s disease residing in long-term care (LTC) settings, including nursing homes. This enrollment marks a key step in the Company’s commitment to generating robust, practice-relevant evidence that complements previous clinical trial data and supports broader use of ZUNVEYL in populations with high unmet needs.
Alzheimer’s disease remains one of the most pressing challenges in modern medicine. Despite significant advances in understanding the disease, patients in long-term care facilities often experience complex care needs, including cognitive decline, neuropsychiatric symptoms, and challenges related to safety and tolerability of medications. Traditional clinical trials, while crucial for regulatory approval, often do not fully capture the realities of routine clinical practice, particularly in institutional settings. Recognizing this gap, Alpha Cognition designed the BEACON study to generate real-world evidence that reflects the day-to-day experiences of patients, healthcare providers, and caregivers in long-term care environments.
The BEACON study is a post-approval, multi-center initiative aimed at evaluating ZUNVEYL’s impact on cognition, neuropsychiatric symptoms, safety, and overall tolerability. ZUNVEYL, Alpha Cognition’s lead therapy, is specifically formulated to address cognitive and neuropsychiatric impairments associated with Alzheimer’s disease. By examining its effectiveness in a real-world LTC population, the study seeks to provide clinicians with actionable insights that extend beyond the controlled conditions of previous clinical trials. The study is designed to enroll approximately 200 patients across multiple clinical sites, representing a broad spectrum of LTC settings and patient demographics. This diverse cohort is expected to provide a comprehensive understanding of how ZUNVEYL performs in routine clinical care, including its efficacy in improving cognitive function and alleviating behavioral symptoms that frequently burden both patients and caregivers.
Kurt Grady, Vice President of Medical Affairs at Alpha Cognition, emphasized the significance of this milestone, stating, “Enrollment of the first patient in the BEACON study represents a significant step forward for Alpha Cognition. This study is designed to generate real-world clinical evidence in the nursing home environment, where the need for effective and well-tolerated therapies is particularly high. If positive, these data have the potential to further strengthen the clinical foundation for ZUNVEYL and support our ongoing commercial launch by providing meaningful insights for healthcare providers, patients, and caregivers.”
The BEACON study is structured to capture a wide range of clinical outcomes over the course of the study period. Efficacy assessments will include standardized cognitive measures and evaluation of neuropsychiatric symptoms, while safety and tolerability will be monitored closely through the collection of adverse event data. This comprehensive approach is intended to provide a clear and nuanced picture of ZUNVEYL’s real-world performance, informing both clinical decision-making and patient management strategies. In addition, by focusing on the long-term care population, BEACON addresses an area of significant unmet need, as these patients often present with more advanced disease and complex comorbidities than those typically enrolled in earlier-phase trials.
The insights gained from the BEACON study are expected to have multiple downstream benefits. For healthcare providers, the data may offer practical guidance on patient selection, dosing, and management of neuropsychiatric symptoms in LTC residents. For caregivers, understanding the potential effects of ZUNVEYL on cognition and behavior could help improve daily care and quality of life for patients. Furthermore, the study’s findings may inform ongoing post-market evaluation, regulatory reporting, and future research initiatives designed to optimize Alzheimer’s care in institutional settings.
Alpha Cognition anticipates completing enrollment of the BEACON study cohort and following patients for a defined period to assess outcomes systematically. The Company expects to report topline results in the fourth quarter of 2026. These results will provide critical data on how ZUNVEYL performs in real-world LTC settings and will complement prior clinical trial evidence to support both clinical and commercial objectives.
The launch of BEACON aligns with Alpha Cognition’s broader strategy to advance innovative therapies that address the complex needs of patients with neurodegenerative diseases. By focusing on real-world effectiveness, the Company is emphasizing not only regulatory approval but also meaningful impact on patient outcomes in everyday care. This approach reflects a growing trend in the pharmaceutical industry to complement traditional clinical trial evidence with real-world data, helping to bridge the gap between clinical research and practical clinical application.
Alzheimer’s disease continues to pose a major public health challenge worldwide, with millions of individuals affected and the burden on long-term care facilities steadily increasing. By conducting the BEACON study, Alpha Cognition aims to provide actionable insights that can improve patient care, guide therapeutic decision-making, and ultimately contribute to better outcomes for patients living with Alzheimer’s disease. The study represents a meaningful step toward translating the promise of ZUNVEYL into tangible benefits for patients, caregivers, and the broader healthcare system.
In summary, the enrollment of the first patient in the BEACON study is a pivotal moment for Alpha Cognition. The study’s focus on real-world effectiveness, comprehensive assessment of cognition and neuropsychiatric symptoms, and attention to safety and tolerability underscore the Company’s commitment to addressing the needs of Alzheimer’s patients in long-term care settings. With topline results expected in the fourth quarter of 2026, the BEACON study has the potential to significantly enhance the clinical understanding of ZUNVEYL and strengthen its role as a therapeutic option in this vulnerable patient population.
